Regulatory StrategyREG-002Publishedv1.0.0

FDA/EMA Alignment Pack

Harmonize your global regulatory strategy

~45s runtime3 evidence sources3 regulatory mappingsUpdated Dec 2025

Summary

Maps FDA and EMA regulatory requirements side-by-side, identifies alignment opportunities, and flags divergent expectations to support global development planning.

Detailed Description

The FDA/EMA Alignment Pack enables sponsors to develop harmonized global regulatory strategies by systematically comparing FDA and EMA requirements across clinical, nonclinical, and CMC domains. It draws on guidance documents from both agencies, ICH harmonization guidelines, and published analyses of regulatory divergence.

The pack performs a structured comparison of FDA and EMA expectations for your development program, identifying areas of alignment where a single dataset can satisfy both agencies and flagging areas of divergence requiring region-specific strategies. It maps parallel scientific advice opportunities and joint review mechanisms.

Deliverables include a regulatory alignment matrix, a divergence analysis with mitigation strategies, and a global development plan framework optimized for simultaneous FDA and EMA submissions.

Evidence Sources

SourceTypeDescriptionRefresh
FDA Guidance LibraryREGULATORYComplete FDA guidance library across clinical, nonclinical, and CMC domainsMonthly
EMA Scientific GuidelinesREGULATORYEMA scientific guidelines, reflection papers, and CHMP position statementsMonthly
ICH Harmonization GuidelinesREGULATORYICH guidelines representing harmonized standards across FDA, EMA, and other regulatory authoritiesQuarterly

Regulatory Mapping

ICHICH M4

The Common Technical Document

PRIMARY
ICHICH E17

General Principles for Planning and Design of Multi-Regional Clinical Trials

PRIMARY
EMAEMA/CHMP/ICH/135/1995

Guideline on the Common Technical Document for the Registration of Medicinal Products

PRIMARY

Agent Transparency

When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.

🔍

Evidence Retriever

brew-retriever-v3

Step 1

Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.

Confidence floor: 85%Avg latency: 4-8s
🧬

Domain Analyzer

brew-domain-analyst-v2

Step 2

Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.

Confidence floor: 80%Avg latency: 6-12s
📊

Evidence Synthesizer

brew-synthesizer-v2

Step 3

Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.

Confidence floor: 82%Avg latency: 8-15s

Output Validator

brew-validator-v1

Step 4

Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.

Confidence floor: 90%Avg latency: 2-4s

Sample Outputs

Regulatory Alignment Matrix

XLSX

Side-by-side comparison of FDA and EMA requirements across all CTD modules

Divergence Analysis

PDF

Detailed analysis of regulatory divergences with mitigation strategies and cost-benefit assessment

Global Development Plan Framework

PDF

Integrated global development plan optimized for simultaneous FDA/EMA submissions

Deliverables included

  • FDA/EMA regulatory alignment matrix
  • Divergence analysis with mitigation strategies
  • Global development plan framework
  • Parallel scientific advice strategy
  • Regional labeling considerations analysis

Related Disease & Biomarker Mappings

Therapeutic AreaDisease FamilyKey BiomarkersRelevance
Cross-TherapeuticRegulatory Strategy
N/A — regulatory focus
Primary
OncologyAccelerated Approval Programs
ORRDORctDNA response
Secondary

Related Packs in Regulatory Strategy

Version History

v1.0.0CurrentNovember 14, 2025

Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.

v0.9.0October 15, 2025

Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.

v0.1.0September 15, 2025

Initial draft — core evidence retrieval pipeline and output schema established.

Need a Custom Evidence Pack?

Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.

Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.